We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.49B
Turnover
10.26%
1-Year Est. Return
208.7%
This Fund
S&P 500
This Quarter
Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
(+23%)
Cap. Flow
+$76.6M
Cap. Flow
% of AUM
3.78%
Top 10 Holdings %
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
1.2
years
Top 20 Avg Time Held Equity + Options
1.1
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1.2
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$71M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$60.3M |
| 3 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$44.3M |
| 4 |
Nightstar Therapeutics plc American Depositary Shares
NITE
|
+$38.2M |
| 5 |
Insmed
INSM
|
+$37.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$66.3M |
| 2 |
Elevance Health
ELV
|
+$43.6M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$35M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$32M |
| 5 |
Penumbra
PEN
|
+$31.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.27% |
| 2 | Financials | 3.41% |
| 3 | Miscellaneous | 1.69% |
| 4 | Communication Services | 0.62% |
| 5 | Energy | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
DELISTED
CATALENT, INC.
CTLT
| $5.89M | 0.29% |
147,663
+1,700
| +1% | +$63K |
2017 Q1
2 quarters
|
|
52
Fate Therapeutics
FATE
$231M
| $5.62M | 0.28% |
1,419,058
| – | – |
2015 Q2
9 quarters
|
|
53
Ovid Therapeutics
OVID
$441M
| $3.77M | 0.19% |
451,182
+2,401
| +0.5% | +$20K |
2017 Q2
1 quarter
|
|
|
NDRM
54
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $2.98M | 0.15% |
76,729
-478,367
| -86% | -$17.6M |
2015 Q3
8 quarters
|
|
55
Aclaris Therapeutics
ACRS
$514M
| $2.61M | 0.13% |
100,960
+6,400
| +7% | +$172K |
2016 Q4
3 quarters
|
|
56
Aurinia Pharmaceuticals
AUPH
$2.23B
| $2.08M | 0.1% |
332,310
| – | – |
2015 Q4
7 quarters
|
|
57
DELISTED
Hologic
HOLX
| $734K | 0.04% |
+20,000
| New | +$807K |
2017 Q3
0 quarters
|
|
58
Neurocrine Biosciences
NBIX
$13.9B
| $407K | 0.02% |
6,640
| – | – |
2017 Q1
2 quarters
|
|
59
UnitedHealth
UNH
$365B
| $356K | 0.02% |
1,820
| – | – |
2016 Q3
4 quarters
|
|
60
Nektar Therapeutics
NKTR
$1.29B
| $350K | 0.02% |
972
| – | – |
2017 Q2
1 quarter
|
|
|
LHCG
61
DELISTED
LHC Group LLC
LHCG
| $235K | 0.01% |
+3,310
| New | +$212K |
2017 Q3
0 quarters
|
|
|
SHPG
62
DELISTED
Shire pic
SHPG
| $208K | 0.01% |
+1,360
| New | +$213K |
2017 Q3
0 quarters
|
|
63
DELISTED
Adverum Biotechnologies
ADVM
| $81K | ﹤0.01% |
2,224
| – | – |
2016 Q2
5 quarters
|
|
|
CSLT
64
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $44K | ﹤0.01% |
10,229
| – | – |
2016 Q2
5 quarters
|
|
|
65
Agios Pharmaceuticals
AGIO
$1.93B
| – | – |
-681,165
| Closed | -$35M | – |
|
66
Brookdale Senior Living
BKD
$2.41B
| – | – |
-12,110
| Closed | -$178K | – |
|
67
DELISTED
Blueprint Medicines
BPMC
| – | – |
-367,537
| Closed | -$18.6M | – |
|
|
68
Elevance Health
ELV
$92.9B
| – | – |
-231,886
| Closed | -$43.6M | – |
|
69
Edwards Lifesciences
EW
$50.8B
| – | – |
-654,000
| Closed | -$25.8M | – |
|
70
CALL
Puma Biotechnology
PBYI
$543M
| – | – |
-101,500
| Closed | -$8.87M | – |
|
71
Prothena Corp
PRTA
$436M
| – | – |
-509,698
| Closed | -$27.6M | – |
|
|
NSTG
72
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-866,819
| Closed | -$14.3M | – |
|
|
CLVS
73
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
-152,000
| Closed | -$14.2M | – |
|
|
GBT
74
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-631,283
| Closed | -$17.3M | – |
|
|
AGN
75
DELISTED
Allergan plc
AGN
| – | – |
-1,200
| Closed | -$292K | – |
|
Similar funds
FCM
MM
WA
ACB
LCS
GAM
MFWP
PMG
Redmile Group's Q3 2017 Portfolio in Review
As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.
On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.
- Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
- Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
- Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
- Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
- Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
- Redmile Group opened 15 new positions and closed 14 in Q3 2017.
- Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.
Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.